These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16684076)

  • 21. Renal osteodystrophy in children on maintenance haemodialysis.
    Mehls O; Krempien B; Ritz E; Schärer K; Schüler HW
    Proc Eur Dial Transplant Assoc; 1973; 10(0):197-201. PubMed ID: 4802577
    [No Abstract]   [Full Text] [Related]  

  • 22. Assessment of bone mineral metabolism derangements by K/DOQI guidelines in haemodialysis patients at Rawalpindi.
    Khan DA; Fatima-Tuz-Zuhra ; Khan FA; Saif I
    J Pak Med Assoc; 2009 Feb; 59(2):64-7. PubMed ID: 19260564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [PTH and bone metabolism in chronic dialysis patients].
    Fukagawa M; Kazama J; Shigematsu T
    Rinsho Byori; 2001 Mar; 49(3):236-8. PubMed ID: 11307321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.
    Shastri J; Tran A; Covit A; Pepe J; Sherman RA
    J Ren Nutr; 2008 Jul; 18(4):370-4. PubMed ID: 18558302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysis.
    Van Eps CL; Jeffries JK; Anderson JA; Bergin PT; Johnson DW; Campbell SB; Carpenter SM; Isbel NM; Mudge DW; Hawley CM
    Nephrology (Carlton); 2007 Jun; 12(3):224-33. PubMed ID: 17498116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcium mass balances during standard bicarbonate hemodialysis and long-hour slow-flow bicarbonate hemodialysis.
    Basile C; Libutti P; Di Turo AL; Tundo S; Maselli P; Casucci F; Losurdo N; Teutonico A; Vernaglione L; Lomonte C
    J Nephrol; 2011; 24(6):742-8. PubMed ID: 21360470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No effect of vitamin K1 supplementation on biochemical bone markers in haemodialysis patients.
    Reichel H
    Nephrol Dial Transplant; 1999 Jan; 14(1):249-50. PubMed ID: 10052531
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association of chronic kidney disease-mineral bone disorder and cardiovascular risk.
    Eddington H; Kalra PA
    J Ren Care; 2010 May; 36 Suppl 1():61-7. PubMed ID: 20586901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compliance with mineral metabolism targets in haemodialysis patients: moving backwards?
    Palomares I; Ramos R; Martin-Malo A; Merello JI; Praga M; Luño J; de Francisco AL;
    Blood Purif; 2013; 36(2):122-31. PubMed ID: 24217176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Radiological features of abnormal calcium metabolism in dialysis patients (author's transl)].
    Ritz E; Kuhn HM; Krempien B; Heuck F; Müller W; Kerlé W; Aschermann C
    Fortschr Geb Rontgenstr Nuklearmed; 1973 Aug; 119(2):194-202. PubMed ID: 4357583
    [No Abstract]   [Full Text] [Related]  

  • 32. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
    Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ
    Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study.
    Gallieni M; Cucciniello E; D'Amaro E; Fatuzzo P; Gaggiotti A; Maringhini S; Rotolo U; Brancaccio D;
    J Nephrol; 2002; 15(2):165-70. PubMed ID: 12018633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. National haemodialysis guidelines: an assessment of compliance from 2001-2003.
    Bannister KM; Snelling P;
    Nephrology (Carlton); 2006 Apr; 11(2):90-6. PubMed ID: 16669967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chronic kidney disease (CKD) and bone. Targets of serum calcium, phosphate, and parathyroid hormone levels and their controls in maintenance dialysis patients].
    Akiba T
    Clin Calcium; 2009 Apr; 19(4):537-44. PubMed ID: 19329833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal osteodystrophy and its treatment.
    Duursma SA; Mees EJ
    Neth J Med; 1973; 16(2):101-7. PubMed ID: 4705764
    [No Abstract]   [Full Text] [Related]  

  • 37. [Dialysis bone disease in children. Six cases (author's transl)].
    Luciani JC; Ferran JL; Dumas ML; Meunier P; Dumas R
    Nouv Presse Med; 1977 Nov; 6(39):3616-9. PubMed ID: 607175
    [No Abstract]   [Full Text] [Related]  

  • 38. Histological, hormonal, biochemical and radiological evaluation of vit. D therapy in osteodystrophy patients on RDT.
    Brancaccio D; Graziani G; Faccini JM; Banfi G; Pedoja G; Watson L
    J Urol Nephrol (Paris); 1976; 82(4-5):359-62. PubMed ID: 940182
    [No Abstract]   [Full Text] [Related]  

  • 39. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
    Tahara H
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vitamin A status of patients with chronic renal failure in relation to renal osteodystrophy].
    Stein G; Abendroth K; Kokot F; Keil E; Schöne S; Wessel G; Fünfstück R; Sperschneider H
    Z Urol Nephrol; 1985 Mar; 78(3):159-65. PubMed ID: 4002896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.